Gilead image

Gilead expands UK presence with new London HQ

pharmafile | February 10, 2015 | News story | Research and Development, Sales and Marketing Cambridge, Gilead, London, NICE, UK, johnson, medcity, sovaldi, uxbridge 

Gilead is to create a new UK commercial secondary headquarters in central London doubling its UK workforce to 600 by the end of this year.

The plans will also see the expansion of its international operations in Uxbridge and R&D-focussed headquarters in Cambridge. The developments represent an increased investment by the company of £13 million.

The Boston-based firm is looking to boost its capacity in Britain after reporting impressive fourth quarter sales for 2014.

Gilead’s presence in the UK market was also enhanced via NICE’s recent final draft guidance for Sovaldi (sofosbuvir), a treatment for hepatitis C which has shown it can effectively cure the liver disease in over 90% of patients in just 12 weeks.

Gilead’s announcement happens to coincide with the Mayor of London Boris Johnson’s whistle-stop tour of Boston, where he is attempting to drum up new business for the UK capital.

Johnson is in the US to promote life sciences and discuss MedCity, a scheme aiming to forge links with academic institutions outside London, as it looks to create a ‘golden triangle’ with links to Oxford and Cambridge.

Commenting on the programme when it was first announced, Johnson said: “London has an immensely rich heritage in medical research that I want to do much more to support. We have the brains and the money right here, we just need a dedicated team to pull it all together.”

On Gilead’s UK expansion plans yesterday he added: “Gilead and Mobiquity’s moves to London further underline the growing importance of the life sciences industry in the UK as we look to ensure that this crucial sector becomes a key contributor to the capital’s growth and health.”

Gilead now joins other pharma firms also strengthening ties with Britain, which include New York-based Merck that last year invested £42 million to create a new licensing hub in London. Others have followed suit such as Pfizer whose new gene therapy unit is being based in the capital.

Dr Eliot Forster, who is the executive chair of MedCity, concludes: “The UK and USA are terrifically well-matched life sciences partners, and I’m delighted to see the traffic across the Atlantic increasing.

“London and the south east is in the midst of a sustained period of enormous ambition and investment in life sciences, and that is attracting great people and companies who enrich our ecosystem further.

“Gilead and Mobiquity are excellent examples – very different companies doing very different things, both at the forefront of the changing healthcare environment.”

Tom Robinson

Related Content

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the …

NICE shares draft guidance for AI’s use in radiotherapy treatment planning

The National Institute for Health and Care Excellence (NICE) has shared draft guidance surrounding nine …

Latest content